Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide
AssigneeBoehringer Ingelheim International GmbH
InventorsChristoph Hoenke, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Sara Frattini, Riccardo Giovannini, Scott Hobson
Life of this patent
Estimating the term…
Abstract
The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
Claims15
A method of treating cognitive impairment in bipolar disorder or cognitive impairment in schizoaffective disorder in a subject comprising administering to the subject an effective amount of a compound of formula (I)
- wherein
- A is selected from the group Aa consisting of
- wherein above mentioned groups are substituted with one R5 and one R6;
- R1 is selected from the group R1a consisting of
- halogen, C1-3-alkyl- and C3-6-cycloalkyl-
- wherein the above mentioned C1-3-alkyl-, and C3-6-cycloalkyl-groups may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, NC— and HO—;
- R2 is selected from the group R2a consisting of
- aryl and heteroaryl,
- wherein the above mentioned aryl and heteroaryl-groups may optionally be substituted with 1 to 5 substituents R4;
- R3 is selected from the group R3a consisting of
- H— and C1-3-alkyl-,
- wherein the above mentioned C1-3-alkyl-groups may optionally be substituted with 1 to 7 substituents independently from each other selected from the group consisting of halogen;
- R4 is independently from each other selected from the group R4a consisting of
- halogen, NC—, HO—, C1-4-alkyl- and C1-3-alkyl-O—
- wherein the above mentioned C1-4-alkyl- and C1-3-alkyl-O-groups may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO— and F—;
- R5 is selected from the group R5a consisting of
- H—, halogen, NC—, HO— and C1-3-alkyl-,
- wherein the above mentioned C1-3-alkyl-group may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO— and F—
- or R5 and R6 together form an group O═;
- R6 is selected from the group R6a consisting of
- H—, halogen, NC—, HO— and C1-3-alkyl-,
- wherein the above mentioned C1-3-alkyl-group may optionally be substituted with 1 to 5 substituents independently selected from the group consisting of HO— and F—
- or R5 and R6 together form a group O═;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.